This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Nasal Decongestion and Obstructive Sleep Apnea

This study has been completed.
Information provided by:
University of Zurich Identifier:
First received: February 27, 2008
Last updated: December 21, 2009
Last verified: December 2009
Whether impaired nasal breathing contributes to sleep related breathing disturbances has not been known. Therefore, the purpose of the study is to compare the effect of xylometazoline, a drug that decongests the nasal mucosa when applied locally, with placebo in terms of sleep and nocturnal breathing and daytime performance.

Condition Intervention Phase
Obstructive Sleep Apnea Syndrome Rhinitis Drug: xylometazoline Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Does Nasal Decongestion Improve Obstructive Sleep Apnea ?

Resource links provided by NLM:

Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • sleep related breathing disturbances sleep efficiency daytime sleepiness [ Time Frame: at end of one week treatment ]

Enrollment: 12
Study Start Date: January 2004
Study Completion Date: April 2005
Primary Completion Date: April 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
nasal application of xylometazoline
Drug: xylometazoline
xylometazoline (0.1 % solution, 3 drops, 0.15 mg) in each nostril
Other Name: Otrivin
Placebo Comparator: 2
nasal application of placebo
Drug: xylometazoline
xylometazoline (0.1 % solution, 3 drops, 0.15 mg) in each nostril
Other Name: Otrivin


Ages Eligible for Study:   20 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Obstructive sleep apnea syndrome (excessive sleepiness, apnea/hypopnea index >10/h)
  • Chronic nasal congestion (complaint of impaired nasal breathing that interfered with subjective sleep quality on at least 3 nights per week during at least the last 3 months)

Exclusion Criteria:

  • Nasal surgery within the last 6 months
  • Current treatment with nasal decongestants or topical steroids
  • Sleep disorders other than obstructive sleep apnea
  • Internal medical or psychiatric disorders that interfered with sleep
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00630474

Pulmonary Division, University Hospital Zurich, Switzerland
Zurich, Switzerland, CH-8091
Pulmonary Division, University Hospital Zurich
Zurich, Switzerland, CH-8091
Sponsors and Collaborators
University of Zurich
Study Chair: Konrad E Bloch, MD University Hospital, Zürich
  More Information

Responsible Party: Konrad E. Bloch, Professor, MD, University Hospital Zurich, Switzerland Identifier: NCT00630474     History of Changes
Other Study ID Numbers: EK-825
Study First Received: February 27, 2008
Last Updated: December 21, 2009

Keywords provided by University of Zurich:
sleep apnea, rhinitis

Additional relevant MeSH terms:
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases
Nose Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Nasal Decongestants
Vasoconstrictor Agents
Respiratory System Agents processed this record on September 21, 2017